到来
发表于 2025-3-21 19:38:37
书目名称Complement Therapeutics影响因子(影响力)<br> http://impactfactor.cn/2024/if/?ISSN=BK0231284<br><br> <br><br>书目名称Complement Therapeutics影响因子(影响力)学科排名<br> http://impactfactor.cn/2024/ifr/?ISSN=BK0231284<br><br> <br><br>书目名称Complement Therapeutics网络公开度<br> http://impactfactor.cn/2024/at/?ISSN=BK0231284<br><br> <br><br>书目名称Complement Therapeutics网络公开度学科排名<br> http://impactfactor.cn/2024/atr/?ISSN=BK0231284<br><br> <br><br>书目名称Complement Therapeutics被引频次<br> http://impactfactor.cn/2024/tc/?ISSN=BK0231284<br><br> <br><br>书目名称Complement Therapeutics被引频次学科排名<br> http://impactfactor.cn/2024/tcr/?ISSN=BK0231284<br><br> <br><br>书目名称Complement Therapeutics年度引用<br> http://impactfactor.cn/2024/ii/?ISSN=BK0231284<br><br> <br><br>书目名称Complement Therapeutics年度引用学科排名<br> http://impactfactor.cn/2024/iir/?ISSN=BK0231284<br><br> <br><br>书目名称Complement Therapeutics读者反馈<br> http://impactfactor.cn/2024/5y/?ISSN=BK0231284<br><br> <br><br>书目名称Complement Therapeutics读者反馈学科排名<br> http://impactfactor.cn/2024/5yr/?ISSN=BK0231284<br><br> <br><br>
种属关系
发表于 2025-3-21 21:26:38
http://reply.papertrans.cn/24/2313/231284/231284_2.png
北极熊
发表于 2025-3-22 01:15:57
http://reply.papertrans.cn/24/2313/231284/231284_3.png
钩针织物
发表于 2025-3-22 06:59:32
http://reply.papertrans.cn/24/2313/231284/231284_4.png
flaggy
发表于 2025-3-22 09:12:14
https://doi.org/10.1057/9780230349414ex signaling mechanisms. Regulation of DAF expression may involve a direct or an indirect effect of at least the estrogen, progesterone, and corticosteroid regulatory pathways. DAF is exploited in multiple pathologic conditions by pathogens and viruses in chronic tissue infection processes. The bind
争吵
发表于 2025-3-22 15:22:06
Captivating Quanzhou Specialties,prevent the generation of BK but also reduce C1q-induced or microbial-ligand-induced inflammatory responses. Employing synthetic peptides and gC1qR deletion mutants, we confirmed previously predicted sites for C1q (residues 75–96) and HK (residues 204–218) and identified additional sites for both C1
争吵
发表于 2025-3-22 18:14:46
http://reply.papertrans.cn/24/2313/231284/231284_7.png
Culpable
发表于 2025-3-22 23:18:22
http://reply.papertrans.cn/24/2313/231284/231284_8.png
Contend
发表于 2025-3-23 02:18:54
Janine O. Ilagan,Melissa S. Juricand (3) avoiding infectious complications or impairment of other important physiological functions of complement when using systemically active complement-blocking agents. This chapter will review data that address these challenges to therapeutic development, with a focus on the development of a nove
惰性气体
发表于 2025-3-23 05:50:40
Klaus Böhmer,Günter Meinardus,Walter SchemppPNH was an appropriate medical condition to develop and to investigate therapeutical complement inhibitors. Indeed, the first complement inhibitor eculizumab, a humanized anti-C5 monoclonal antibody, has been proven safe and effective for the treatment of PNH patients. Chronic treatment with eculizu